Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin + Fludarabine + TBI + SCT in Advanced AML/MDS
NCT00008151Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2000
- Primary completion
- Jul 2002
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started Oct 2000; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00008151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00008151.